vs
BIODESIX INC（BDSX）与BillionToOne, Inc.（BLLN）财务数据对比。点击上方公司名可切换其他公司
BillionToOne, Inc.的季度营收约是BIODESIX INC的2.9倍（$83.5M vs $28.8M）。BillionToOne, Inc.净利率更高（6.8% vs -13.8%，领先20.7%）。BillionToOne, Inc.同比增速更快（117.4% vs 40.8%）。BillionToOne, Inc.自由现金流更多（$6.5M vs $692.0K）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
BDSX vs BLLN — 直观对比
营收规模更大
BLLN
是对方的2.9倍
$28.8M
营收增速更快
BLLN
高出76.6%
40.8%
净利率更高
BLLN
高出20.7%
-13.8%
自由现金流更多
BLLN
多$5.8M
$692.0K
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $83.5M |
| 净利润 | $-4.0M | $5.7M |
| 毛利率 | — | 69.9% |
| 营业利润率 | -6.8% | 11.5% |
| 净利率 | -13.8% | 6.8% |
| 营收同比 | 40.8% | 117.4% |
| 净利润同比 | 51.8% | 138.3% |
| 每股收益（稀释后） | $-3.35 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXBLLN
| Q4 25 | $28.8M | — | ||
| Q3 25 | $21.8M | $83.5M | ||
| Q2 25 | $20.0M | — | ||
| Q1 25 | $18.0M | — | ||
| Q4 24 | $20.4M | — | ||
| Q3 24 | $18.2M | $38.4M | ||
| Q2 24 | $17.9M | — | ||
| Q1 24 | $14.8M | — |
净利润BDSXBLLN
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-8.7M | $5.7M | ||
| Q2 25 | $-11.5M | — | ||
| Q1 25 | $-11.1M | — | ||
| Q4 24 | $-8.3M | — | ||
| Q3 24 | $-10.3M | $-14.9M | ||
| Q2 24 | $-10.8M | — | ||
| Q1 24 | $-13.6M | — |
毛利率BDSXBLLN
| Q4 25 | — | — | ||
| Q3 25 | — | 69.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率BDSXBLLN
| Q4 25 | -6.8% | — | ||
| Q3 25 | -32.4% | 11.5% | ||
| Q2 25 | -48.6% | — | ||
| Q1 25 | -50.9% | — | ||
| Q4 24 | -32.5% | — | ||
| Q3 24 | -47.3% | -32.9% | ||
| Q2 24 | -46.0% | — | ||
| Q1 24 | -74.4% | — |
净利率BDSXBLLN
| Q4 25 | -13.8% | — | ||
| Q3 25 | -40.0% | 6.8% | ||
| Q2 25 | -57.3% | — | ||
| Q1 25 | -61.8% | — | ||
| Q4 24 | -40.4% | — | ||
| Q3 24 | -56.5% | -38.8% | ||
| Q2 24 | -60.3% | — | ||
| Q1 24 | -91.9% | — |
每股收益（稀释后）BDSXBLLN
| Q4 25 | $-3.35 | — | ||
| Q3 25 | $-1.16 | $0.10 | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $-5.02 | — | ||
| Q3 24 | $-1.40 | $-1.47 | ||
| Q2 24 | $-0.08 | — | ||
| Q1 24 | $-0.14 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $195.2M |
| 总债务越低越好 | $50.0M | $55.0M |
| 股东权益账面价值 | $-2.5M | $-239.5M |
| 总资产 | $87.5M | $327.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDSXBLLN
| Q4 25 | $19.0M | — | ||
| Q3 25 | $16.6M | $195.2M | ||
| Q2 25 | $20.7M | — | ||
| Q1 25 | $17.6M | — | ||
| Q4 24 | $26.2M | — | ||
| Q3 24 | $31.4M | — | ||
| Q2 24 | $42.2M | — | ||
| Q1 24 | $11.5M | — |
总债务BDSXBLLN
| Q4 25 | $50.0M | — | ||
| Q3 25 | $50.0M | $55.0M | ||
| Q2 25 | $50.0M | — | ||
| Q1 25 | $40.0M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $40.1M | — | ||
| Q1 24 | $40.1M | — |
股东权益BDSXBLLN
| Q4 25 | $-2.5M | — | ||
| Q3 25 | $-1.7M | $-239.5M | ||
| Q2 25 | $1.1M | — | ||
| Q1 25 | $11.1M | — | ||
| Q4 24 | $20.9M | — | ||
| Q3 24 | $27.9M | $-242.9M | ||
| Q2 24 | $36.3M | — | ||
| Q1 24 | $-5.5M | — |
总资产BDSXBLLN
| Q4 25 | $87.5M | — | ||
| Q3 25 | $88.7M | $327.5M | ||
| Q2 25 | $87.7M | — | ||
| Q1 25 | $86.2M | — | ||
| Q4 24 | $97.2M | — | ||
| Q3 24 | $102.7M | — | ||
| Q2 24 | $115.8M | — | ||
| Q1 24 | $87.2M | — |
负债/权益比BDSXBLLN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 43.95× | — | ||
| Q1 25 | 3.62× | — | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $13.8M |
| 自由现金流经营现金流 - 资本支出 | $692.0K | $6.5M |
| 自由现金流率自由现金流/营收 | 2.4% | 7.7% |
| 资本支出强度资本支出/营收 | 0.3% | 8.8% |
| 现金转化率经营现金流/净利润 | — | 2.42× |
| 过去12个月自由现金流最近4个季度 | $-23.5M | — |
8季度趋势，按日历期对齐
经营现金流BDSXBLLN
| Q4 25 | $778.0K | — | ||
| Q3 25 | $-8.9M | $13.8M | ||
| Q2 25 | $-6.6M | — | ||
| Q1 25 | $-8.6M | — | ||
| Q4 24 | $-4.1M | — | ||
| Q3 24 | $-10.7M | — | ||
| Q2 24 | $-18.6M | — | ||
| Q1 24 | $-15.3M | — |
自由现金流BDSXBLLN
| Q4 25 | $692.0K | — | ||
| Q3 25 | $-8.9M | $6.5M | ||
| Q2 25 | $-6.6M | — | ||
| Q1 25 | $-8.7M | — | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-10.9M | — | ||
| Q2 24 | $-20.5M | — | ||
| Q1 24 | $-15.5M | — |
自由现金流率BDSXBLLN
| Q4 25 | 2.4% | — | ||
| Q3 25 | -41.0% | 7.7% | ||
| Q2 25 | -33.1% | — | ||
| Q1 25 | -48.3% | — | ||
| Q4 24 | -24.2% | — | ||
| Q3 24 | -60.1% | — | ||
| Q2 24 | -114.3% | — | ||
| Q1 24 | -104.9% | — |
资本支出强度BDSXBLLN
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.2% | 8.8% | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 10.7% | — | ||
| Q1 24 | 1.6% | — |
现金转化率BDSXBLLN
| Q4 25 | — | — | ||
| Q3 25 | — | 2.42× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
